October 2024 Publications
- Implications of subclinical tuberculosis for vaccine trial design and global effect Churchyard GJ, Houben RMGJ, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG. Lancet Microbe. 2024 Oct;5(10):100895. doi: 10.1016/S2666-5247(24)00127-7. Epub 2024 Jul 1.
- Research Progress on Liposome Pulmonary Delivery of Mycobacterium tuberculosis Nucleic Acid Vaccine and Its Mechanism of Action. Zhang D, Zhao H, Li P, Wu X, Liang Y. J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):284-298. doi: 10.1089/jamp.2023.0025. Epub 2024 Apr 26.
- Tuberculosis vaccine – A timely analysis of the drawbacks for the development of novel vaccines. Jeyachandran DS, Pusam Y. Indian J Tuberc. 2024 Oct;71(4):453-459. doi: 10.1016/j.ijtb.2023.12.002. Epub 2023 Dec 23.
- Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans. Voogd L, van Wolfswinkel M, Satti I, White AD, Dijkman K, Gela A, van Meijgaarden KE, Franken KLMC, Marshall JL, Ottenhoff THM, Scriba TJ, McShane H, Sharpe SA, Verreck FAW, Joosten SA. Vaccines (Basel). 2024 Oct 1;12(10):1129. doi: 10.3390/vaccines12101129.
- The frequency of CD38+ alveolar macrophages correlates with early control of M. tuberculosis in the murine lung. Pisu D, Johnston L, Mattila JT, Russell DG. Nat Commun. 2024 Oct 2;15(1):8522. doi: 10.1038/s41467-024-52846-w.
- Multilevel Proteomics Reveals Epigenetic Signatures in BCG-Mediated Macrophage Activation. Schaefer Z, Iradukunda J, Lumngwena EN, Basso KB, Blackburn JM, Parker IK. Mol Cell Proteomics. 2024 Oct 2;23(11):100851. doi: 10.1016/j.mcpro.2024.100851. Epub ahead of print.
- DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies. Kazakova A, Zhelnov P, Sidorov R, Rogova A, Vasileva O, Ivanov R, Reshetnikov V, Muslimov A. Front Immunol. 2024 Oct 3. doi: 10.3389/fimmu.2024.1457327.
- Advances in the development of new vaccines for tuberculosis and Brazil’s role in the effort forward the end TB strategy. Junqueira-Kipnis AP, Leite LCC, Croda J, Chimara E, Carvalho ACC, Arcêncio RA. Mem Inst Oswaldo Cruz. 2024 Oct 4;119:e240093. doi: 10.1590/0074-02760240093.
- Immune mechanisms of protection against Mycobacterium tuberculosis-centers. Dang Q, Eichelberg K, Vázquez-Maldonado N, Boggiano C, Leitner WW, Ramachandra L, Deckhut-Augustine A, Read SW. Front Immunol. 2024 Oct 8;15:1429250. doi: 10.3389/fimmu.2024.1429250.
- CD4+ T cells re-wire granuloma cellularity and regulatory networks to promote immunomodulation following Mtb reinfection. Bromley JD, Ganchua SKC, Nyquist SK, Maiello P, Chao M, Borish HJ, Rodgers M, Tomko J, Kracinovsky K, Mugahid D, Nguyen S, Wang QD, Rosenberg JM, Klein EC, Gideon HP, Floyd-O’Sullivan R, Berger B, Scanga CA, Lin PL, Fortune SM, Shalek AK, Flynn JL. Immunity. 2024 Oct 8;57(10):2380-2398.e6. doi: 10.1016/j.immuni.2024.08.002. Epub 2024 Aug 29. PMID: 39214090; PMCID: PMC11466276.
- The potential impact of new TB vaccines on the burden of TB in people living with HIV in South Africa. Sumner T, Clark RA, Prys-Jones TO, Bakker R, Churchyard G, White RG. AIDS. 2024 Oct 11. doi: 10.1097/QAD.0000000000004038. Epub ahead of print.
- Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction. Grace PS, Peters JM, Sixsmith J, Lu R, Luedeman C, Fenderson BA, Vickers A, Slein MD, Irvine EB, McKitrick T, Wei MH, Cummings RD, Wallace A, Cavacini LA, Choudhary A, Proulx MK, Sundling C, Källenius G, Reljic R, Ernst JD, Casadevall A, Locht C, Pinter A, Sasseti CM, Bryson BD, Fortune SM, Alter G. bioRxiv [Preprint]. 2024 Oct 11:2024.10.07.617070. doi: 10.1101/2024.10.07.617070.
- Functional genomic analysis of the 68-1 RhCMV- Mycobacteria tuberculosis vaccine reveals an IL-15 response signature that is conserved with vector attenuation. Sung CJ, Whitmore LS, Smith E, Chang J, Tisoncik-Go J, Barber-Axthelm A, Selseth A, Feltham S, Ojha S, Hansen SG, Picker LJ, Gale M Jr. Front Immunol. 2024 Oct 15;15:1460344. doi: 10.3389/fimmu.2024.1460344.
- Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a Mycobacterium tuberculosis challenge mouse model – A comparison. Szachniewicz MM, Neustrup MA, van den Eeden SJF, van Meijgaarden KE, Franken KLMC, van Veen S, Koning RI, Limpens RWAL, Geluk A, Bouwstra JA, Ottenhoff THM. Int J Pharm. 2024 Oct 16:124842. doi: 10.1016/j.ijpharm.2024.124842. Epub ahead of print..
- Bacillus Calmette-Guérin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau. Berendsen MLT, Bles P, de Bree LCJ, Jensen KJ, Jensen CC, Wejse C, Mendes DV, Netea MG, Benn CS. Vaccine. 2024 Oct 17;42(26):126439. doi: 10.1016/j.vaccine.2024.126439. Epub ahead of print.
- Coarse-Graining the Recognition of a Glycolipid by the C-Type Lectin Mincle Receptor. Noriega M, Corey RA, Haanappel E, Demange P, Czaplicki G, Atkinson RA, Chavent M. J Phys Chem B. 2024 Oct 17;128(41):9935-9946. doi: 10.1021/acs.jpcb.4c03242. Epub 2024 Oct 5.
- MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates. Woodworth JS, Contreras V, Christensen D, Naninck T, Kahlaoui N, Gallouët AS, Langlois S, Burban E, Joly C, Gros W, Dereuddre-Bosquet N, Morin J, Liu Olsen M, Rosenkrands I, Stein AK, Krøyer Wood G, Follmann F, Lindenstrøm T, Hu T, Le Grand R, Pedersen GK, Mortensen R. Nat Commun. 2024 Oct 17;15(1):8959. doi: 10.1038/s41467-024-52863-9.
- Vaccines for Global Health: Progress and Challenges. Knisely JM, Erbelding E. J Infect Dis. 2024 Oct 18:jiae511. doi: 10.1093/infdis/jiae511. Epub ahead of print.
- Advanced technologies for the development of infectious disease vaccines. Gupta A, Rudra A, Reed K, Langer R, Anderson DG. Nat Rev Drug Discov. 2024 Oct 21. doi: 10.1038/s41573-024-01041-z. Epub ahead of print.
- Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9/CXCL10 axis in tuberculosis. Liu X, Yang M, Xu P, Du M, Li S, Shi J, Li Q, Yuan J, Pang Y. Cell Mol Immunol. 2024 Oct 22. doi: 10.1038/s41423-024-01230-1. Epub ahead of print. PMID: 39438693.
- Single cell transcriptional analysis of human adenoids identifies molecular features of airway microfold cells. Alvarez-Arguedas S, Mazhar K, Wangzhou A, Sankaranarayanan I, Gaona G, Lafin JT, Mitchell RB, Price TJ, Shiloh MU. bioRxiv [Preprint]. 2024 Oct 22:2024.10.19.619143. doi: 10.1101/2024.10.19.619143.
- A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts. Valencia-Hernandez AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, Pedroza-Roldan C, Seifert J, Aceves-Sanchez MJ, Burciaga-Flores M, Gutierrez-Ortega A, Del Pozo-Ramos L, Flores-Valdez MA, Kupz A. Vaccine. 2024 Oct 24;42(24):126291. doi: 10.1016/j.vaccine.2024.126291. Epub 2024 Sep 5.
- Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development. Karunakaran KP, Yu H, Jiang X, Chan QWT, Sigola L, Millis LA, Chen J, Tang P, Foster LJ, Brunham RC. Vaccine. 2024 Oct 24;42(24):126266. doi: 10.1016/j.vaccine.2024.126266. Epub 2024 Sep 3.
- Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach. Zhu Y, Shi J, Wang Q, Zhu Y, Li M, Tian T, Shi H, Shang K, Yin Z, Zhang F. PLoS One. 2024 Oct 28;19(10):e0309560. doi: 10.1371/journal.pone.0309560.
- Self-Adjuvanting Adenoviral Nanovaccine for Effective T-Cell-Mediated Immunity and Long-Lasting Memory Cell Activation against Tuberculosis. Sowndharya CK, Mehnath S, Ponbharathi A, Jeyaraj M. ACS Infect Dis. 2024 Oct 28. doi: 10.1021/acsinfecdis.4c00619. Epub ahead of print.
- The TB vaccine clinical trial centre directory: An inventory of clinical trial centres in Sub-Saharan Africa. Pelzer PT, Holleman M, Helinski MEH, Weinberg AL, Buis J, Beattie P, Nyirenda T, van Rest J, Voss G. PLoS One. 2024 Oct 28;19(10):e0292981. doi: 10.1371/journal.pone.0292981.
- Structure and function of Mycobacterium tuberculosis EfpA as a lipid transporter and its inhibition by BRD-8000.3. Li D, Zhang X, Yao Y, Sun X, Sun J, Ma X, Yuan K, Bai G, Pang X, Hua R, Guo T, Mi Y, Wu L, Zhang J, Wu Y, Liu Y, Wang P, Wong CCL, Chen XW, Xiao H, Gao GF, Gao F. Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2412653121. doi: 10.1073/pnas.2412653121. Epub 2024 Oct 23.
- Mycobacterium w – a promising immunotherapeutic intervention for diseases. Stefan K, Gordon R, Rolig A, Honkala A, Tailor D, Davis LE, Modi RI, Joshipura M, Khamar B, Malhotra SV. Front Immunol. 2024 Oct 29;15:1450118. doi: 10.3389/fimmu.2024.1450118.
- Markov field network model of multi-modal data predicts effects of immune system perturbations on intravenous BCG vaccination in macaques. Wang S, Myers AJ, Irvine EB, Wang C, Maiello P, Rodgers MA, Tomko J, Kracinovsky K, Borish HJ, Chao MC, Mugahid D, Darrah PA, Seder RA, Roederer M, Scanga CA, Lin PL, Alter G, Fortune SM, Flynn JL, Lauffenburger DA. Cell Syst. 2024 Oct 29:S2405-4712(24)00298-9. doi: 10.1016/j.cels.2024.10.001. Epub ahead of print.
- Immune correlates of protection as a game changer in tuberculosis vaccine development. Wang J, Fan XY, Hu Z. NPJ Vaccines. 2024 Oct 30;9(1):208. doi: 10.1038/s41541-024-01004-w.
- Transiently boosting Vγ9+Vδ2+ γδ T cells early in Mtb coinfection of SIV-infected juvenile macaques does not improve Mtb host resistance. Larson EC, Ellis AL, Rodgers MA, Gubernat AK, Gleim JL, Moriarty RV, Balgeman AJ, de Menezes YT, Ameel CL, Fillmore DJ, Pergalske SM, Juno JA, Maiello P, Chishti HB, Lin PL, Godfrey DI, Kent SJ, Pellicci DG, Ndhlovu LC, O’Connor SL, Scanga CA. Infect Immun. 2024 Oct 30:e0031324. doi: 10.1128/iai.00313-24. Epub ahead of print.
- Tuberculosis: How close are we to a new vaccine? Mahase E. BMJ. 2024 Oct 31;387:q2410. doi: 10.1136/bmj.q2410.